جست‌وجوی استاد و پژوهشگر

• Microbiology
• Antimicrobial Resistance
• Bacterial Secretion Systems
• +۴ مورد دیگر

Dr. Luke Allsopp is an Associate Professor in Molecular Bacteriology at the National Heart & Lung Institute (NHLI), part of the Faculty of Medicine at Imperial College London. His research focuses on bacterial secretion systems, antimicrobial resistance, and biofilm formation in pathogens like Pseudomonas aeruginosa. He leads a team within the Respiratory Infections Section at the NHLI, located at the Royal Brompton Campus. Dr. Allsopp holds affiliations with the Centre for Bacterial Resistance Biology, Institute of Infection, and Microbiome Network. He has secured funding from organizations including the BBSRC, Cystic Fibrosis Trust, and LifeArc. His lab explores how bacteria adapt to environmental challenges through secretion systems and biofilm programs, with a special emphasis on chronic respiratory pathogens in cystic fibrosis patients. Research interests include: Gram-negative bacterial secretion systems (e.g., Type VI) Regulation of virulence factors and biofilm dynamics Mechanisms of antibiotic resistance and persistence Host-pathogen interactions in respiratory infections Recent work highlights synergistic drug combinations (e.g., glatiramer acetate with tobramycin) and innovative models predicting CFTR gene therapy impacts on Pseudomonas biofilms. His team collaborates on the UK Cystic Fibrosis Infection Biorepository (UKCFIB) to accelerate antimicrobial development. Advising and grants: Supervises competitive PhD candidates via Presidents Scholarship programs. Major funders include the Academy of Medical Sciences and ESCMID. Lab/Team: Based in the Emmanuel Kaye Building, his group combines functional genomics, metabolomics, and structural biology to dissect bacterial pathogenesis mechanisms.

Joshua Rabinowitzمشاهده پروفایل

استاد

• Cellular Metabolism
• Chemical Biology
• Metabolic Regulation
• +۳ مورد دیگر

Joshua Rabinowitz is a Professor of Chemistry and Director of the Ludwig Princeton Branch at Princeton University. His research focuses on quantitative analysis of cellular metabolism, leveraging advanced mass spectrometry and computational modeling. Key areas include metabolic regulation in microbes (E. coli, yeast), cancer cell metabolism, viral infection impacts, and biofuel production. His lab has pioneered methods to measure metabolites and fluxes, leading to discoveries like novel cancer metabolites and antiviral strategies via fatty acid inhibition. Notable honors include the NIH Pioneer Award and Agilent Thought Leader Award. Research emphasizes systems-level understanding, with projects combining biological experiments, metabolomics, and computation. Recent work explores metabolic heterogeneity in humans, immunotherapy enhancements through metabolic modulation, and metabolic vulnerabilities in cancers like rhabdomyosarcoma. Collaborations include engineering yeast for biofuel production and developing therapeutics targeting metabolic pathways. Lab Website: Rabinowitz Lab Affiliations: Lewis-Sigler Institute for Integrative Genomics, Princeton University Major contributions include identifying metabolic shifts in viral infections, modeling microbial nutrient responses, and advancing technologies for metabolite quantification. Current efforts aim to integrate metabolomic data with enzyme regulation dynamics to predict metabolic networks across organisms.

Jeffrey Wolfمشاهده پروفایل

استاد

• Multiple Myeloma
• Hematology
• Oncology
• +۱۳ مورد دیگر

Jeffrey Wolf, MD, is a Professor in the Department of Medicine at the University of California, San Francisco (UCSF), School of Medicine. He serves as the Director of the Myeloma Program, where he leads clinical and translational research focused on multiple myeloma and plasma cell disorders. His work emphasizes novel immunotherapies, including CAR-T cells, bispecific antibodies, and targeted agents, with a strong commitment to improving patient outcomes through clinical trials. Dr. Wolf’s research interests center on advancing therapeutic strategies for multiple myeloma, particularly BCMA, GPRC5D, CD38, and CD70-targeted therapies. His laboratory and clinical studies explore mechanisms of treatment resistance, T-cell exhaustion, immune-related toxicities, and the myeloma surfaceome to identify new targets. He actively investigates the interplay between immunotherapy and host immunity, including vaccine responses in immunocompromised patients. His work spans from basic molecular mechanisms to phase 1 and 2 clinical trials, reflecting a robust translational approach. The 15 most recent publications highlight a consistent focus on immunotherapeutic advances in multiple myeloma. Key themes include CAR-T cell therapy (BCMA, CD70), mechanisms of resistance and toxicity (e.g., T-cell exhaustion, enterocolitis, MAS-L), and novel antibody-based approaches (e.g., targeting GPRC5D, CD38). There is a strong emphasis on clinical translation, with multiple phase 1b and observational studies informing treatment optimization and patient management strategies. Director, Myeloma Program, UCSF Professor, Department of Medicine, UCSF School of Medicine Active principal or co-investigator on numerous clinical trials in multiple myeloma Extensive collaborations with leaders in hematology-oncology including Thomas Martin, Nina Shah, and Arun Wiita Dr. Wolf has mentored numerous researchers and clinicians through his role at UCSF and has contributed to the training of hematologists and oncologists. While specific advisees are not listed in the provided text, his extensive co-authorship network suggests a strong commitment to collaborative science and academic mentorship. He has not received any explicitly listed scientific awards in the provided data, but his publication record in top-tier journals and leadership in clinical trials indicate significant recognition in the field. His work is conducted within the UCSF Myeloma Program, a multidisciplinary team dedicated to research and treatment of plasma cell disorders. The program engages in cutting-edge translational research, clinical trial development, and patient care, with a focus on immunotherapy and personalized medicine approaches.

Nicholas Tonksمشاهده پروفایل

استاد

• Protein Tyrosine Phosphatases
• Signal Transduction
• Cancer Biology
• +۴ مورد دیگر

Nicholas Tonks is a Professor and the Caryl Boies Professor of Cancer Research at Cold Spring Harbor Laboratory (CSHL), with a focus on protein tyrosine phosphatases (PTPs) and their roles in diseases like cancer, diabetes, and neurodegenerative disorders. He leads research at the CSHL Cancer Center, aiming to develop novel therapeutic strategies targeting PTPs. Academic Appointments : Caryl Boies Professor of Cancer Research (1995–present), Associate Director of Shared Resources (CSHL Cancer Center, 1995–present) Education : Ph.D. in Biochemistry (University of Dundee, 1985), B.A. in Biochemistry (Oxford University, 1981) Research Interests : Tonks' work centers on PTPs as critical regulators of cell signaling. His lab has uncovered roles for PTPs in breast cancer, diabetes, and Alzheimer’s disease, including the development of antibodies targeting oxidized PTP1B and small-molecule inhibitors for therapeutic intervention. Scientific Awards : 2019 AAAS Fellow ASBMB Earl and Thressa Stadtman Distinguished Scientist Award (2018) Vallee Foundation Visiting Professorship (2012) Advising and Collaborations : Mentored numerous postdoctoral fellows and graduate students, including Dongyan Song, Zhe Qian, and Navasona Krishnan. Contributed to understanding PTP1B's redox regulation and its implications for ER stress and metabolic diseases. Labs and Teams : Leads the Tonks Laboratory at CSHL, collaborating with institutions like the University of Dundee and Oxford University. Research spans therapeutic targets for Wilson’s disease, diabetes, and cancer, integrating interdisciplinary approaches like proteomics and structural biology.

Edgar Englemanمشاهده پروفایل

استاد

• Immunology
• Cancer Immunotherapy
• Myeloid Cell Biology
• +۱۷ مورد دیگر

Edgar Engleman is a Professor of Pathology and of Medicine (Immunology and Rheumatology) at Stanford University School of Medicine. He is a leading figure in cellular immunology, with major contributions to cancer immunotherapy, immune tolerance, and myeloid cell biology. He holds key affiliations with the Stanford Cancer Institute, Wu Tsai Neurosciences Institute, Bio-X, and the Maternal & Child Health Research Institute (MCHRI). He serves as Co-Director of Tumor Immunology and Immunotherapy and as Medical Director of the Stanford Blood Center. Professor, Department of Pathology, Stanford University Professor, Department of Medicine (Immunology and Rheumatology), Stanford University Co-Director, Tumor Immunology and Immunotherapy, Stanford Cancer Institute Medical Director, Stanford Blood Center Member, Wu Tsai Neurosciences Institute Member, Bio-X Member, Maternal & Child Health Research Institute (MCHRI) Dr. Engleman’s research focuses on the biology of immune cells, especially dendritic cells, macrophages, and neutrophils, in cancer, autoimmunity, organ transplantation, and metabolic and neurodegenerative diseases. His lab was instrumental in developing Sipuleucel-T (Provenge), the first FDA-approved cell-based cancer immunotherapy. Current work includes reprogramming immunosuppressive myeloid cells, studying lymph node-mediated immune tolerance in metastasis, and targeting novel immune checkpoints. His lab also investigates microglia in neurodegeneration and retinoic acid in colorectal cancer immunity. His recent publications (2022–2025) reveal a strong emphasis on myeloid cell function in tumor immunosuppression, mechanisms of metastasis, and novel therapeutic strategies including neutrophil activation, GPR65 inhibition, and EPO/EPOR blockade. His work integrates advanced technologies such as multiplex imaging, deep sequencing, and machine learning (e.g., CELESTA algorithm) to dissect immune cell interactions and tissue architecture. Notable scientific contributions include: Development of the first FDA-approved cancer vaccine (Provenge) Discovery of lymph node-induced immune tolerance promoting metastasis Identification of novel myeloid immune checkpoints Therapeutic reprogramming of tumor-associated myeloid cells Role of microglia in neurodegeneration and its pharmacological targeting Link between retinoic acid deficiency and impaired anti-tumor immunity in colorectal cancer Dr. Engleman actively mentors numerous graduate students and postdoctoral fellows, advising on doctoral theses and research projects across immunology, cancer biology, and pathology. His lab receives substantial research funding, enabling extensive studies in mouse models and human tissues. He also contributes to education through directed reading and research courses. The Engleman Lab functions as a collaborative Cellular Immunology Lab (CIL), fostering innovation and high-risk research. It utilizes cutting-edge tools including flow cytometry and mass cytometry to map immune responses system-wide. Ongoing efforts aim to translate mechanistic discoveries into clinical applications for cancer, autoimmune disorders, and transplant tolerance.

Charlene Blakeمشاهده پروفایل

استاد بالینی

• Cardiothoracic Anesthesiology
• Aptamer Therapeutics
• Anticoagulation
• +۷ مورد دیگر

Charlene Blake, MD, PhD is a Clinical Professor in the Department of Anesthesiology and Perioperative Care at the University of California, San Francisco (UCSF) . She is affiliated with multiple UCSF campuses, including Mission Bay, Mount Zion, and Parnassus, and specializes in Adult Cardiac anesthesiology. Her dual training in medicine and genetics underscores her interdisciplinary approach to research and clinical practice. MD, Medical Scientist Training Program, Duke University School of Medicine (2010) PhD, Genetics and Genomics, Duke University Graduate School (2009) BA, Chemistry, Fisk University (2002) Cardiothoracic Anesthesiology Fellowship, Washington University in St. Louis (2015) Anesthesiology Residency, Washington University in St. Louis (2014) Diversity, Equity, and Inclusion Champion Training, University of California (2018) Dr. Blake's research lies at the intersection of molecular therapeutics and clinical anesthesiology, with a strong focus on RNA aptamers , antidote development , and drug safety . Her work explores the use of aptamers as reversible anticoagulants and their applications in stroke and hemorrhage. She also investigates pharmacogenomics , particularly CYP2D6 and metoprolol metabolism, and is deeply engaged in understanding and addressing ethnic disparities in medical training and inclusive medical technology design . Her publications reflect a dual trajectory: one in translational molecular medicine , focusing on aptamer control and antidote systems, and another in health equity , examining microaggressions, diversity in anesthesiology, and the impact of skin pigmentation on medical devices. This combination highlights her commitment to both scientific innovation and social responsibility in medicine. Development of universal antidotes for aptamer therapeutics Reversible aptamers for stroke and hemorrhage PAI-1-specific aptamers in cancer metastasis Metoprolol pharmacokinetics and CYP2D6 Ethnic disparities in fellowship training Inclusive design of light-based medical devices Dr. Blake is actively involved in advancing diversity and inclusion in academic medicine, having completed formal training in this area and publishing on microaggressions and equity. Her research has been supported by NIH grants (e.g., R01 HL065222, U54 CA119347), and she collaborates with prominent scientists in nucleic acid therapeutics. She advises on clinical and translational research and contributes to policy discussions on equity in medical education and practice. She is affiliated with research teams focused on aptamer-based therapeutics and health equity initiatives at UCSF, working within interdisciplinary labs that bridge molecular biology, anesthesiology, and public health. Her future work is likely to expand on personalized anticoagulation strategies and inclusive medical technologies.

Hani Goodarziمشاهده پروفایل

دانشیار

• Computational Biology
• RNA Biology
• Cancer Genomics
• +۳ مورد دیگر

Hani Goodarzi, PhD , is an Associate Professor in the Department of Biochemistry and Biophysics at the University of California, San Francisco (UCSF), with dual affiliation to the Arc Institute and Helen Diller Cancer Center. His laboratory employs a systems biological framework integrating computational and experimental approaches to investigate metastatic progression in cancer and neurodegenerative diseases. Princeton University PhD in Quantitative & Computational Biology Postdoctoral Fellow, Rockefeller University (Cancer Systems Biology) NIH R01 Grants (2016–2026) Research Themes : Machine learning for in silico functional genomics Evolutionary dynamics of oncRNA regulatory modules in cancer Post-transcriptional control via tiRNA fragments and RNA methylation RNA structural element discovery using pyPAGE algorithms Scientific Recognition : Vilcek Prize for Creative Promise (2022) NIH K99/R00 Award (2015) Tri-Institutional Breakout Prize (2014) Blavatnik Regional Award (2015) Laboratory Impact : Developed Deep Generative AI for early-stage lung cancer detection Identified ENPP1 as innate immune checkpoint in breast cancer Created pyPAGE framework for gene-set enrichment analysis

Randolph Ashtonمشاهده پروفایل

استاد

• Neural tissue engineering
• Vascular tissue engineering
• Regenerative therapies for the central nervous system
• +۳ مورد دیگر

Randolph Ashton is a Professor in the Department of Biomedical Engineering at the University of Wisconsin-Madison College of Engineering. He directs the Stem Cell Bioprocessing and Regenerative Biomaterials Laboratory, where his team engineers novel materials and methodologies for lineage-specific differentiation of human pluripotent stem cells. His interdisciplinary research bridges biomaterials science, stem cell biology, and tissue engineering to develop regenerative therapeutic strategies. His educational background includes: PhD (2007) from Rensselaer Polytechnic Institute BS (2002) from Hampton University Ashton's research focuses on neural and vascular tissue engineering , with specialization in regenerative therapies for the central nervous system. His laboratory employs microfabrication, molecular biology, recombinant protein engineering, and automated live-cell imaging to investigate cellular microenvironmental factors regulating stem cell fate. Current work emphasizes developing high-throughput screening methods and tissue-engineered scaffolds for generating complex tissue structures in vitro. His recent publications reveal a strong trajectory in neural organoid development, CNS vascularization, and microphysiological systems. The research demonstrates quantitative approaches to understanding stem cell differentiation, with applications spanning from fundamental developmental biology to clinical regenerative medicine. Key technological innovations include advanced microelectrode arrays and high-throughput screening platforms for neural tissue engineering. Notable awards include: 2023 AIMBE Fellowship 2020 WARF Innovation Award 2018 UW-Madison College of Engineering Equity & Diversity Award 2017 NSF CAREER Award 2016 Regenerative Medicine Workshop Young Investigator Award Ashton actively mentors graduate students through thesis research (BME 890, BME 990) and teaches core courses including Biological Interactions with Materials (BME 430). His laboratory operates as an interdisciplinary team bringing together engineering, biology, and materials science expertise to develop regenerative therapies, with current focus on central nervous system applications and expanding interests in vascular and muscular tissues. The Stem Cell Bioprocessing and Regenerative Biomaterials Laboratory maintains active collaborations across disciplines and continues to develop novel approaches for high-order tissue structure generation using human pluripotent stem cells. Current research directions include expanding into vascular and muscular tissue systems while refining quantitative methodologies for stem cell microenvironment characterization.

Vasileios Bekiarisمشاهده پروفایل

دانشیار

• Immunology
• T Cell Signaling
• Inflammation
• +۵ مورد دیگر

Vasileios Bekiaris is an Associate Professor and Groupleader at the Department of Health Technology, Technical University of Denmark, specializing in Experimental & Translational Immunology with a focus on T-Cell Signaling and Development. His research explores the roles of γδ T cells, cytokines, and immune regulation in health and disease. Research Interests: γδ T cell biology and immunotherapy Cytokine signaling (IL-17, IL-27, interferons) Immune checkpoint inhibitors in cancer and infection Aging-related immune barrier function Apoptosis regulation via cIAP ligases Translational immunology applications Supervision: Bekiaris mentors multiple PhD candidates in projects involving iPSC-T cell engineering, neonatal immunity, and small molecule immunotherapeutics. Key collaborations include researchers at DTU and international institutions.

Enric Llorens Bobadillaمشاهده پروفایل

استادیار

• Regenerative Neurobiology
• Stem Cell Biology
• Systems Biology
• +۵ مورد دیگر

Enric Llorens Bobadilla is an Assistant Professor at the Department of Cell and Molecular Biology, Karolinska Institutet, leading the Systems regenerative neurobiology – Enric Llorens Group . His research focuses on promoting central nervous system regeneration through stem cell biology , systems biology , computational biology , and molecular engineering in mouse models of disease . Fields of Research : Medical Biotechnology (Cell Biology, Molecular Biology, Biochemistry) and Neurosciences Key research approaches include single-cell genomics, spatial genomics, computational biology, gene delivery, and CNS injury models. The lab develops synthetic gene circuits to study regenerative responses and spatial molecular profiling technologies for understanding pathological cell states. Scientific awards include the 2022 ERC Starting Grant 2022 Swedish Foundation for Strategic Research Future Leaders 2022 StratNeuro Startup Grant The lab collaborates with teams across Karolinska Institutet and employs PhD students (Gabriel Gomez Rydholm, Timm Häneke, Adrián Martínez Martín, Lei Wang) and researchers (Simon Perrin, Margherita Zamboni) to advance CNS regeneration studies.

Luke Boulterمشاهده پروفایل

پژوهشگر

• Wnt Signaling
• Liver Regeneration
• Tissue Repair
• +۶ مورد دیگر

Luke Boulter is a Reader and Cancer Research UK Fellow at the University of Edinburgh , affiliated with the Institute of Genetics and Cancer and the MRC Human Genetics Unit . His research focuses on Wnt signaling in liver tissue repair and cancer progression. BSc (Hons) in Molecular Cell Biology – University of York (2004) PhD – University of Edinburgh (2011) Luke’s lab investigates how Wnt signaling regulates liver regeneration, bile duct development, and cholangiocarcinoma. Key themes include: Canonical and non-canonical Wnt pathway dynamics Epithelial-mesenchymal interactions in disease Therapeutic targeting of signaling networks His recent publications highlight work on: Biliary tree patterning (2024) TGFβ-ECM-integrin axis in polycystic liver disease (2023) CRISPR-based genetic heterogeneity analysis in cholangiocarcinoma (2022) Scientific awards include: Cancer Research UK Fellowship Leverhulme Trust Early Career Fellowship Current projects funded by MRC, CRUK, UKRI, and Chief Scientist Office focus on repatterning cystic environments, targeting tumor-initiating cells, and pharmacological Wnt modulation.

Stephanie Panierمشاهده پروفایل

استاد پژوهشی

• Genome Stability
• DNA Damage Response
• Aging Research
• +۴ مورد دیگر

Dr. Stephanie Panier serves as a Max Planck Research Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany, and as a Principal Investigator at the Institute for Genome Stability in Aging and Disease within the Medical Faculty of the University of Cologne. Her research program investigates the fundamental mechanisms by which cells maintain genome stability through sophisticated DNA damage response pathways. Her academic journey includes: PhD in Molecular Genetics from the University of Toronto (2008-2013) under Prof. Daniel Durocher Postdoctoral training at the Francis Crick Institute in London (2013-2019) with Prof. Simon Boulton Undergraduate studies in Biology at Ruprecht-Karls-Universität Heidelberg, Germany (2001-2006) Dr. Panier's laboratory focuses on two central questions in genome stability research: how DNA damage response pathways interact with telomere maintenance mechanisms, and how RNAs and RNA-binding proteins organize chromatin-based responses to DNA lesions. Her team employs cutting-edge cell biological and omics approaches to identify and characterize RNA-binding proteins at DNA damage sites, mapping their chromatin dynamics and interactions following genotoxic stress. This research has significant implications for understanding aging-associated diseases driven by genomic instability, including cancer and neurodegeneration. Analysis of her publication record reveals consistent contributions to understanding DNA repair mechanisms, with recent work expanding into cancer biology, telomere maintenance in alternative lengthening pathways, and the emerging role of RNA metabolism in genome stability. Her scientific achievements have been recognized through: Vivash Award for best PhD thesis (2013) FEBS Excellence Award (2023) EMBO Long-Term Fellowship (2013-2014) Vanier Canada Graduate Scholarship (2010-2013) Boehringer Ingelheim Fonds PhD Fellowship (2008-2010) EIRR21st Fellowship (2023) Dr. Panier actively contributes to the scientific community through leadership roles including Vice Coordinator of the DFG Research Unit FOR5504 (2023-2026), membership on the advisory board of the German Society for Research on DNA Repair since 2022, and representation on the Biology and Medicine Section of the Max Planck Society's scientific council since 2022. She also serves as a Principal Investigator in the Cologne Excellence Cluster 'Cellular Stress Responses in Aging-Associated Diseases' (CECAD). Her laboratory comprises postdoctoral researchers and PhD students working collaboratively to advance our understanding of genome stability mechanisms in aging, with current projects focusing on RNA-binding proteins in DNA damage response and telomere maintenance pathways.

• Pharmacology
• Cholesterol Metabolism
• Alzheimer's Disease
• +۵ مورد دیگر

Bianca Papotti is a fixed-term Researcher at the Department of Food and Pharmaceutical Sciences, University of Parma. Her academic career spans interdisciplinary research in Pharmacology Cholesterol Metabolism Neurodegenerative Diseases Cardiovascular Pathology Immunometabolism . She teaches courses including Experimental Pharmacology and Food Toxicology. Her research focuses on the role of PCSK9 and cholesterol efflux in Alzheimer's Disease Atherosclerosis Rheumatoid Arthritis Lipoprotein Biology Inflammatory Disease Drug Development . Key trends in her publications (3 in 2025, 12 in 2024) reveal strong emphasis on PCSK9 inhibition mechanisms, cholesterol-immune crosstalk in rheumatoid arthritis, and fasting interventions in lipid-related pathologies. Her work has explored PCSK9's neuroinflammatory effects ABCA1/ABCG1 transporter dynamics Macrophage cholesterol loading Natural compound screening HDL dysfunction in diabetes Covid-19 lipid interactions .

Dietmar Schlosserمشاهده پروفایل

پژوهشگر

• Environmental Biotechnology
• Microbial Ecology
• Fungal Biotechnology
• +۵ مورد دیگر

Dr. Dietmar Schlosser is a Group Leader in Environmental Mycology at the Department of Applied Microbial Ecology within the Helmholtz Center for Environmental Research - UFZ since 2005. His research program focuses on fungal biodegradation of environmental pollutants, particularly synthetic polymers, micro-pollutants, and recalcitrant organic compounds. Education : Diploma in Biology (1990), Friedrich Schiller University Jena PhD in Technical Microbiology (1993), Friedrich Schiller University Jena His research integrates ecological principles with applied biotechnology , emphasizing fungal biochemistry, physiology, and enzymology. Key projects include: TapNature (2021-2027): Exploiting natural fungal systems for bioeconomy FINEST Microplastics (2022-2027): Sustainable materials management PUreValue (2024-2027): Polyurethane biodegradation for upcycling CLEANER (2023-2026): Water cycle resilience in cities Article trends reveal expertise in mycoremediation , lignocellulose valorization , and fungal attack on synthetic polymers , with recent work spanning environmental engineering, microbiology, and biochemical monitoring techniques. He maintains active collaborations with institutions across Europe and contributes to sustainable technology development through his leadership in Environmental Mycology .

Soner Doğanمشاهده پروفایل

استاد

• Breast Cancer
• Calorie Restriction
• Molecular Biology
• +۳ مورد دیگر

Prof. Soner Doğan is a Professor at Yeditepe University's Faculty of Medicine, Department of Medical Biology. He holds a PhD in Medical Biology from the University of Minnesota and a Bachelor's in Veterinary Science from Ankara University. His research bridges oncology, epigenetics, and metabolic regulation, with a focus on breast cancer mechanisms and calorie restriction. Research interests span: Breast Cancer Pathobiology : Investigating leptin/adiponectin signaling and epigenetic modifications in tumor development. Calorie Restriction : Examining intermittent vs. chronic dietary interventions for cancer prevention and aging. Aging and Frailty : Identifying biomarkers and molecular pathways in age-related diseases using murine models. His publications emphasize molecular oncology, with recurring themes in adipokine signaling, DNA methylation, and transcriptomic profiling. Articles frequently utilize transgenic mouse models and RNA-seq to explore metabolic and immune interactions in cancer. Awards & Honors: Professional Development Grant, Education Minnesota Foundation AICR Scholarship for Cancer Research Conference Advising & Grants : Supervised 11+ Master's/PhD theses on topics like nanoparticle drug delivery and epigenetic regulation. Secured major grants including TÜBİTAK 1001 (€395K) for breast cancer epigenetics and COST Action CA17129 for cardiovascular transcriptomics. Affiliations : Leads projects at Yeditepe’s molecular biology labs and collaborates internationally (e.g., EU-CardioRNA COST Action). Holds administrative roles as Department Coordinator and Ethics Committee member.